Leggett & Platt (LEG) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
18 Jan, 2026Executive summary
Q3 2024 sales were $1.1 billion, down 6% year-over-year, with volume down 4% and persistent weak demand in residential, automotive, and specialty segments.
Adjusted EPS for Q3 was $0.32, down from $0.36 in Q3 2023; reported EPS was $0.33.
A $675 million non-cash goodwill impairment in 2024 drove a net loss for the nine months.
Restructuring and efficiency initiatives are progressing, with $124 million debt paid down in Q3 and facility consolidations across all segments.
Strategic review underway, including potential sale of the Aerospace business and a sharply reduced dividend to prioritize deleveraging.
Financial highlights
Q3 2024 sales: $1,102 million, down 6% year-over-year; YTD sales: $3,327 million, down 8%.
Q3 EBIT was $78 million, down 15% year-over-year; adjusted EBIT was $76 million, down $10 million; adjusted EBIT margin was 6.9%.
Q3 adjusted EBITDA was $112 million, down 14% year-over-year; margin was 10.2%.
Operating cash flow for Q3 was $95 million, down $48 million year-over-year; YTD operating cash flow was $183 million, down $168 million.
Net debt to adjusted EBITDA was 3.78x at quarter end; total debt $1.9 billion, cash $277 million, liquidity $748 million.
Outlook and guidance
2024 sales guidance lowered to $4.3–$4.4 billion, down 7–9% from 2023; volume expected down mid-single digits across all segments.
Full-year adjusted EPS now expected at $1.00–$1.10, down from prior $1.10–$1.25; reported EPS expected to be a loss of $3.56–$3.71 due to impairment.
Adjusted EBIT margin guidance reduced to 6.0–6.4%.
Operating cash flow for 2024 expected at $300 million; capex $100 million; dividends $135 million.
Restructuring plan expected to be substantially complete by end of 2025, with annualized EBIT benefit of $50–$60 million.
Latest events from Leggett & Platt
- Disciplined restructuring and innovation drive margin improvement and cash flow amid market headwinds.LEG
Investor presentation10 Mar 2026 - 2026 outlook: flat-to-down sales, margin gains, and focus on debt reduction amid weak demand.LEG
Q4 202512 Feb 2026 - Q2 loss driven by $675M impairment, lower sales, and restructuring; dividend cut for deleveraging.LEG
Q2 20242 Feb 2026 - Adjusted EPS up to $0.24 despite 7% sales drop; 2025 outlook and deleveraging focus maintained.LEG
Q1 202527 Dec 2025 - Restructuring and cost actions drive margin gains amid weak demand and a cautious 2025 outlook.LEG
Q4 202423 Dec 2025 - Shareholders will vote on directors, auditor, executive pay, and a revised Flexible Stock Plan.LEG
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, executive pay, and stock plan amendment.LEG
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, compensation, and stock plan.LEG
Proxy Filing1 Dec 2025 - Sales fell 6% but margins and adjusted EPS improved, with guidance and balance sheet strengthened.LEG
Q2 202516 Nov 2025